IRadimed Corporation
HealthcareNASDAQ:IRMD · NASDAQ Capital Market
-$2.66 today
Vol 0.17M · Avg 0.14M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.8%
avg 16.6%
ROIC
21.0%
avg 15.1%
ROA
20.7%
avg 14.2%
Analysis
ROE is currently the strongest return metric at 23.8% versus its period average of 16.6%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Roger E. Susi | Founder, Chairman, Chief Executive Officer & President | $780,598.00 | — | 73 | $2.16M | 16.93% |
John F. Glenn | Chief Financial Officer & Corporate Secretary | $609,994.00 | — | 64 | $8,907.00 | 0.07% |
Jeff Chiprin | Chief Commercial Officer | $529,360.00 | — | 60 | $1,150.00 | <0.01% |
Randy Waddell | Vice President of Worldwide Sales & Marketing | $446,151.00 | — | — | — | — |
Lynn Neuhardt | Vice President of Research & Development | $354,946.00 | — | — | — | — |
Chris Williamson | Executive Vice President of Continuous Improvement & Information Technology | — | — | — | — | — |
Matt Garner | Controller | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
131
$21.36M
Net Sentiment
$21.36M
Net selling
Most Active
Susi Roger E.
117 transactions
1–10 of 131
Analysis
Insiders reported 0 buys worth $0.00 and 131 sells worth $21.36M over the last 12 months. That adds up to net selling of $21.36M. Susi Roger E. was the most active insider with 117 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +46.7% | +13.3% (14yr)1 analysts |
| Revenue | N/A | N/A | +42.0% | +11.3% (14yr)1 analysts |
| Net Income | N/A | N/A | +55.0% | +13.8% (14yr)1 analysts |
| EBIT | N/A | N/A | +57.6% | +12.4% (14yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +57.6% over three years. Forward estimates point to Net Income at +13.8% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
AxoGen, Inc.
NASDAQ:AXGN
$2.29B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.14B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
Cronos Group Inc.
NASDAQ:CRON
$1.00B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
InMode Ltd.
NASDAQ:INMD
$817.88M
MiMedx Group, Inc.
NASDAQ:MDXG
$536.20M
Claritev Corporation
NYSE:CTEV
$526.61M
Who manages IRMD?
IRadimed Corporation (IRMD) lists 7 active executives. The top listed executive is Chris Williamson, Executive Vice President of Continuous Improvement & Information Technology.
Are IRMD insiders buying or selling?
Recent insider activity shows net selling of $23.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.